In addition, erlotinib is a highly specific tyrosine kinase inhibitor that can reversibly inhibit epidermal growth factor receptor mutations and is mainly used for targeted therapy after the failure of chemotherapy for non-small cell lung cancer (NSCLC). Here, EGFR is linked to non-small cell lung carcinoma.